Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 3,370.00
+85.00 (2.59%)
At close: Sep 9, 2026
Genome & Company Revenue
Genome & Company had revenue of 6.25B KRW in the quarter ending June 30, 2026, with 7.66% growth. This brings the company's revenue in the last twelve months to 24.46B, up 1.84% year-over-year. In the year 2025, Genome & Company had annual revenue of 24.59B, down -11.38%.
Revenue (ttm)
24.46B
Revenue Growth
+1.84%
P/S Ratio
7.21
Revenue / Employee
n/a
Employees
n/a
Market Cap
176.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.59B | -3.16B | -11.38% |
| Dec 31, 2024 | 27.74B | 13.45B | 94.07% |
| Dec 31, 2023 | 14.30B | 211.39M | 1.50% |
| Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% |
| Dec 31, 2021 | 451.25M | 300.66M | 199.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 51.04B |
| NIBEC | 22.60B |
| Prestige Biologics | 18.03B |
| Bio Solution | 17.39B |
| TiumBio | 15.00B |
| curacle co.,ltd. | 8.24B |
| Y-Biologics | 3.17B |
| Kangstem Biotech | 3.03B |